Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KBP 042

Next Previous
X
Search
Drug Profile

KBP 042

Alternative Names: DACRA; DACRA 042; KBP042

Latest Information Update: 05 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KeyBioScience
  • Developer Eli Lilly and Company; KeyBioScience
  • Class Antihyperglycaemics; Insulin sensitisers; Peptides
  • Mechanism of Action Amylin receptor agonists; Calcitonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 06 Feb 2019 Discontinued - Phase-II for Type 2 diabetes mellitus (Adjunctive treatment) in United Kingdom, Romania, Moldova, Poland, Denmark, Czech Republic (SC)
  • 31 Jul 2018 KeyBioscience completes a phase II trial in Type-2 diabetes mellitus (Adjunctive treatment) in Czech Republic, Denmark, United Kingdom, Romania, Moldova, Poland (SC) (EudraCT2017-001061-24) (NCT03230786)
  • 23 Aug 2017 Phase-II clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in Denmark, Czech Republic (SC) (NCT03230786) (EudraCT2017-001061-24)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top